CUTIA-B: CU-40102 China Phase III clinical trial results accepted for presentation in electronic poster format at the 8th Chinese Medical Association Hair Academic Conference

CUTIA-B announced that the Phase III clinical trial results of its product CU-40102 for treating androgenetic alopecia have been accepted for presentation at the 8th National Hair Conference of the Chinese Medical Association. This product is the world's first topically applied finasteride approved for this condition. Data shows that the efficacy of the CU-40102 group after 24 weeks is significantly better than the placebo group, with good safety and no serious adverse events. The NDA for CU-40102 has also been accepted by the National Medical Products Administration